January 6th, 2014
•Evaluated in syngeneic immunocompetent hosts, cancer stem cell (CSC) based dendritic cell (DC) vaccine demonstrated significantly higher antitumor immunity than traditional DC vaccines pulsed with heterogeneous bulk tumor cells.
Related Videos
Quantitative Assessment of Immune Cells in the Injured Spinal Cord Tissue by Flow Cytometry: a Novel Use for a Cell Purification Method
Analysis of Pulmonary Dendritic Cell Maturation and Migration during Allergic Airway Inflammation
Mass Spectrometric Analysis of Glycosphingolipid Antigens
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
Monitoring Dendritic Cell Migration using 19F / 1H Magnetic Resonance Imaging
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved